Rituximab in Severe Seronegative Juvenile Myasthenia Gravis: Review of the Literature

Abstract Myasthenia gravis is an autoimmune neuromuscular disorder caused by circulating antibodies that block acetylcholine receptors at the postsynaptic neuromuscular junction. A wide range of symptomatic therapy with acetylcholinesterase inhibitors and immunotherapy such as corticosteroids, azath...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric neurology 2012-09, Vol.47 (3), p.209-212
Hauptverfasser:	Koul, Roshan, MD, Al Futaisi, Amna, MD, Abdwani, Reem, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetylcholine receptors Acetylcholinesterase Airway Extubation Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal, Murine-Derived - adverse effects Antibodies, Monoclonal, Murine-Derived - therapeutic use Antigens, CD19 - analysis Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use azathioprine Biological and medical sciences Blepharoptosis - etiology Child, Preschool Corticoids Cyclosporins Diplopia - etiology Diseases of striated muscles. Neuromuscular diseases Female Humans Immunoglobulins Immunotherapy Intravenous administration Literature reviews Lymphocyte Count Medical sciences Morbidity Mortality Myasthenia gravis Myasthenia Gravis - drug therapy Neurology Neuromuscular junctions neuromuscular system Pediatrics Plasmapheresis Prednisone - administration & dosage Prednisone - therapeutic use Quality of life Remission Respiration, Artificial Rituximab Side effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!